Technophage attends the JLabs EMEA CEO Summit 2024

Technophage attends the JLabs EMEA CEO Summit 2024

Recently, Technophage CEO Miguel Garcia, attended the prestigious JLABS EMEA CEO Summit 2024. This event, held in the exciting city of London, brought together leaders from the biotech and life sciences industries. It is an incredible platform for collaboration,...
Technophage honored with a Healthcare & Pharmaceutical Award

Technophage honored with a Healthcare & Pharmaceutical Award

For eight years in a row, the Healthcare & Pharmaceutical Awards have recognized the pioneers transforming our healthcare field. We are thrilled to announce that Technophage has been recognized as the “Most Innovative Biopharmaceutical Company 2023 –...
TZ-161 one step closer to clinical trials in spinal cord injury

TZ-161 one step closer to clinical trials in spinal cord injury

Technophage is thrilled to share that TZ-161 product is now one step closer to potentially becoming a pioneering repurposed treatment for patients suffering from acute spinal cord injury. This innovative product, currently undergoing clinical trial application in...